Print

QLT Inc. (QLTI) Shows Positive Efficacy Trends From Data in Plug Combinations in Phase II Studies for Glaucoma Using Latanoprost Punctal Plug Delivery System  
10/25/2012 9:49:11 AM

VANCOUVER, British Columbia, Oct. 24, 2012 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) announced that results from two Phase II clinical studies, PPL GLAU 12 and PPL GLAU 13, demonstrate positive trends (with statistically and clinically significant findings) on the efficacy and safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in subjects with ocular hypertension (OH) and open-angle glaucoma (OAG).
//-->